Fatty Liver Disease Clinical Evidence and Research: What the Studies Show

Introduction

The NASH clinical trial space has produced more data in the last five years than in the preceding twenty. Before 2024, there was no FDA-approved drug for NASH. Now there’s one (resmetirom), and semaglutide is expected to file for a MASH indication based on the ESSENCE trial results. This article reviews every major trial, from the foundational vitamin E data to the newest pipeline molecules, with actual numbers and honest assessments of what the data shows and what it doesn’t.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did the Newsome 2021 Semaglutide Trial Prove?

The Newsome et al. trial, published in the New England Journal of Medicine in November 2021, was the first large randomized controlled trial to test a GLP-1 receptor agonist specifically for NASH. It proved that semaglutide can resolve NASH at rates far exceeding placebo, but left the fibrosis question partially unanswered.

Quick Answer: Semaglutide’s ESSENCE phase 3 trial met both co-primary endpoints: MASH resolution and fibrosis improvement.

Design: Phase 2, double-blind, placebo-controlled. 320 patients with biopsy-confirmed NASH, fibrosis stages F1-F3. Randomized to daily subcutaneous semaglutide 0.1mg, 0.2mg, 0.4mg, or placebo for 72 weeks. Liver biopsies at baseline and week 72.

Primary endpoint: NASH resolution (disappearance of ballooning, with inflammation score of 0 or 1) without worsening of fibrosis.

Results at the 0.4mg dose:

• NASH resolution: 59% vs. 17% placebo (odds ratio 6.87, P<0.001)
• At least one-stage fibrosis improvement: 43% vs. 33% placebo (not statistically significant, P=0.48)
• Mean body weight change: -12.5% vs. -0.6% placebo
• ALT normalization: substantially higher in the semaglutide group (exact percentage varied by definition used)

What it proved: Semaglutide can resolve NASH histologically in a majority of treated patients. The 59% resolution rate at the highest dose was remarkable. The placebo rate of 17% is worth noting. It reflects sampling variability in serial biopsies and spontaneous fluctuation, and it’s consistent with other biopsy-based NASH trials.

What it didn’t prove: Fibrosis improvement wasn’t statistically significant. This was the study’s main limitation. With only 80 patients per arm, the trial was underpowered for this endpoint. The 43% vs. 33% difference trended in the right direction but couldn’t be confirmed statistically.

An important note on dosing: The 0.4mg daily subcutaneous formulation used in this trial was never commercialized. It was a research formulation. All subsequent semaglutide NASH research uses the once-weekly injectable (the same formulation as Wegovy®/Ozempic®). The pharmacokinetics differ, making direct dose-to-dose extrapolation imperfect.

Adverse events: Nausea (42% at 0.4mg vs. 11% placebo), constipation (22% vs. 11%), and vomiting (16% vs. 5%). GI side effects led to discontinuation in approximately 10% of the semaglutide groups. One case of pancreatitis in the semaglutide arm was noted but didn’t establish a causal link.

What Does the ESSENCE Trial Add?

The ESSENCE trial is the phase 3 semaglutide NASH trial that the field was waiting for. It addresses the two main limitations of the phase 2 study: it uses the commercially available weekly formulation, and it’s powered to detect fibrosis improvement.

Design: Phase 3, double-blind, placebo-controlled. Approximately 800 patients with biopsy-confirmed MASH (the new terminology) and fibrosis stages F2-F3. Randomized to once-weekly subcutaneous semaglutide 2.4mg or placebo for 72 weeks. Liver biopsies at baseline and week 72.

Co-primary endpoints:

1. MASH resolution without worsening of fibrosis
2. Fibrosis improvement of at least one stage without worsening of MASH

Interim results (presented 2024): Both co-primary endpoints were met. Semaglutide 2.4mg achieved statistically significant superiority over placebo for both MASH resolution and fibrosis improvement. Exact percentages have been presented at medical conferences, with MASH resolution rates in the 55-65% range and fibrosis improvement showing a meaningful treatment difference.

Why fibrosis matters so much: Fibrosis stage is the single best predictor of liver-related mortality. The Dulai et al. 2017 meta-analysis in Gastroenterology showed that each fibrosis stage increase correlated with a 40-50% increase in all-cause mortality. A drug that can reverse fibrosis doesn’t just treat a lab number. It changes life expectancy.

Regulatory implications: Novo Nordisk has indicated plans to file a supplemental new drug application (sNDA) with the FDA for a semaglutide MASH indication based on ESSENCE data. If approved, semaglutide would become the first GLP-1 with an official liver disease indication.

Weight loss context: The weight loss in ESSENCE was approximately 10-15%, consistent with semaglutide 2.4mg in other populations (STEP trials). This raises the question of how much liver benefit is from weight loss vs. direct hepatic effects. The answer is probably “most from weight loss, some from direct effects,” but the distinction is somewhat academic. The liver improves regardless of mechanism.

What Did the SYNERGY-NASH Trial Show for Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces more weight loss than semaglutide. The SYNERGY-NASH trial tested whether this translates to better liver outcomes.

Design: Phase 2, double-blind, placebo-controlled. Approximately 190 patients with biopsy-confirmed MASH and fibrosis stages F2-F3. Randomized to tirzepatide 5mg, 10mg, or 15mg weekly vs. placebo for 52 weeks. Liver biopsies at baseline and week 52.

Results at the 15mg dose (presented at EASL 2024):

• MASH resolution without fibrosis worsening: approximately 74%
• Fibrosis improvement by at least one stage: approximately 47%
• Mean weight loss: approximately 15.2%
• Relative liver fat reduction by MRI-PDFF: approximately 60-65%

Context: The 74% MASH resolution rate is the highest reported for any drug in a randomized trial. Cross-trial comparison with the Newsome semaglutide data (59%) suggests tirzepatide may be more effective, but the trials differ in patient populations, durations (52 vs. 72 weeks), and biopsy timing. A head-to-head trial would be needed to confirm superiority.

The GIP receptor question: Tirzepatide’s advantage may come from the GIP receptor agonism, the additional weight loss it produces, or both. GIP receptor activation has been shown in preclinical studies to reduce hepatic steatosis through pathways separate from GLP-1. Whether this translates to meaningful additive benefit in humans is still being sorted out.

Next steps: Eli Lilly has launched the SYNERGY-MASH phase 3 program. Phase 3 results are expected in 2026-2027. If the data holds, tirzepatide could be the most effective MASH medication available.

What Did the MAESTRO Trials Prove for Resmetirom?

Resmetirom (Rezdiffra®) is a thyroid hormone receptor-beta (THR-beta) selective agonist. The MAESTRO program includes three phase 3 trials, with MAESTRO-NASH being the one that led to FDA approval.

MAESTRO-NASH design: Phase 3, double-blind, placebo-controlled. 966 patients with biopsy-confirmed NASH and F2-F3 fibrosis. Randomized to resmetirom 80mg, 100mg, or placebo daily for 52 weeks. Published by Harrison et al. in the New England Journal of Medicine, 2024.

Co-primary endpoints:

1. NASH resolution without worsening of fibrosis at week 52
2. Fibrosis improvement by at least one stage without worsening of NASH at week 52

Results at 100mg:

• NASH resolution: 29.9% vs. 9.7% placebo (P<0.001)
• Fibrosis improvement: 25.9% vs. 14.2% placebo (P<0.001)
• LDL cholesterol reduction: approximately 14%
• Triglyceride reduction: approximately 20%
• Weight change: minimal (this is not a weight-loss drug)

Results at 80mg:

• NASH resolution: 25.9% vs. 9.7% placebo
• Fibrosis improvement: 24.2% vs. 14.2% placebo

Both doses met both co-primary endpoints.

How resmetirom works: THR-beta is the predominant thyroid hormone receptor in the liver. Activating it increases hepatic fatty acid oxidation, reduces de novo lipogenesis, and improves lipid metabolism. The selectivity for THR-beta (rather than THR-alpha, which mediates cardiac and bone effects) is what makes resmetirom tolerable. You get liver-specific thyroid hormone effects without tachycardia, osteoporosis, or weight loss.

The approval context: Resmetirom received accelerated FDA approval on March 14, 2024, making it the first drug ever approved specifically for NASH/MASH. Accelerated approval means it was based on surrogate endpoints (histological improvement) rather than clinical outcomes (liver-related mortality). Continued approval depends on confirmatory trial results from the MAESTRO-NASH OLE (open-label extension) and other studies.

MAESTRO-NAFLD-1: A separate phase 3 trial evaluating resmetirom’s effects on liver imaging (MRI-PDFF) rather than biopsy endpoints. Results showed significant liver fat reduction, supporting the histological findings.

Safety: Diarrhea and nausea were the most common side effects but were generally mild. A transient increase in LDL cholesterol occurred in the first few weeks, which then reversed, with net LDL reduction by week 24. This is because resmetirom upregulates hepatic LDL receptors, which takes time to kick in. No serious liver safety signals emerged, which was important given that the drug acts directly on the liver.

What Did the PIVENS Trial Show for Vitamin E and Pioglitazone?

PIVENS (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-Diabetic Patients with NASH) remains one of the most cited NASH trials despite being published in 2010. It established vitamin E as the first treatment shown to resolve NASH in a randomized trial.

Design: Phase 3, double-blind, placebo-controlled. 247 non-diabetic adults with biopsy-confirmed NASH (without cirrhosis). Randomized to vitamin E 800 IU/day, pioglitazone 30mg/day, or placebo for 96 weeks. Published by Sanyal et al. in the New England Journal of Medicine, 2010.

Primary endpoint: A composite score requiring improvement in NAFLD activity score (NAS) by at least 2 points, with at least 1-point improvement in hepatocellular ballooning, and no increase in fibrosis.

Results:

Vitamin E:

• Primary composite: 43% vs. 19% placebo (P=0.001)
• NASH resolution: 36% vs. 21% placebo (P=0.05)
• Fibrosis improvement: not statistically significant

Pioglitazone:

• Primary composite: 34% vs. 19% placebo (P=0.04, but didn’t meet pre-specified significance threshold of 0.025 due to multiple comparisons)
• NASH resolution: 47% vs. 21% placebo (P=0.001)
• Fibrosis improvement: not statistically significant

The odd result: Pioglitazone actually produced higher NASH resolution (47%) than vitamin E (36%), but it didn’t meet the primary composite endpoint due to the pre-specified statistical threshold. Vitamin E met it. This is a quirk of trial design, not a reflection of true superiority.

Limitations: Only non-diabetic patients were enrolled, so the results can’t be extrapolated to the large population of NASH patients with type 2 diabetes. The 96-week duration was long, but the trial didn’t assess durability after treatment cessation.

Long-term safety concerns for vitamin E: The SELECT trial (Klein et al., JAMA, 2011) found that vitamin E 400 IU/day increased prostate cancer risk by 17% in healthy men. The Miller et al. 2005 meta-analysis in Annals of Internal Medicine suggested possible increased all-cause mortality above 400 IU/day. The NASH dose of 800 IU/day exceeds both thresholds.

Key Takeaway: Resmetirom became the first-ever FDA-approved NASH drug in March 2024 based on MAESTRO-NASH data.

What Does the Bariatric Surgery Evidence Show?

Bariatric surgery produces the largest and most durable liver improvements of any intervention, but the randomized trial data is relatively recent.

BRAVES trial (Verrastro et al., Lancet, 2023):

The first randomized controlled trial comparing bariatric surgery to lifestyle intervention for NASH.

Design: 288 patients with BMI 30-45, biopsy-confirmed NASH, and NAS 4 or above. Randomized to Roux-en-Y gastric bypass, sleeve gastrectomy, or lifestyle modification. Biopsies at baseline and 12 months.

Results at 1 year:

• NASH resolution: 57% (bypass), 56% (sleeve), 16% (lifestyle)
• Fibrosis improvement by at least 1 stage: significantly higher with both surgical procedures
• Weight loss: ~30% (bypass), ~25% (sleeve), ~5% (lifestyle)

Lassailly et al. (Gastroenterology, 2020):

A prospective cohort following NASH patients for 5 years after bariatric surgery.

Results:

• NASH resolution at 5 years: 84%
• Mean fibrosis score: decreased significantly
• Some patients who initially improved had recurrence of steatosis at 5 years (16%), suggesting that long-term metabolic vigilance is needed even after surgery

Mathurin et al. (Gastroenterology, 2009):

An earlier prospective study showing that 1 year after bariatric surgery, steatosis resolved in 75% of patients and NASH resolved in 70%.

The cirrhosis caveat: Bariatric surgery in patients with compensated cirrhosis is feasible but carries higher risk. A 2017 study by Jan et al. in Surgery for Obesity and Related Diseases found that cirrhotic patients had higher complication rates after bariatric surgery (about 21% vs. 10% in non-cirrhotics). Decompensated cirrhosis is generally a contraindication.

What’s in the Clinical Pipeline?

Several next-generation molecules are in mid-to-late-stage development:

Survodutide (Boehringer Ingelheim)

A dual glucagon/GLP-1 receptor agonist. The glucagon component increases hepatic fatty acid oxidation and energy expenditure, adding to the GLP-1 effects on appetite and insulin sensitivity.

Phase 2 data (presented at EASL 2024): In patients with MASH and F1-F3 fibrosis, survodutide produced dose-dependent liver fat reduction of up to 80% by MRI-PDFF at the highest dose. MASH resolution rates were in the 60-70% range. Weight loss was approximately 15-19%.

Phase 3 (the FALCON program) is ongoing.

Pemvidutide (Altimmune)

Another dual glucagon/GLP-1 agonist. Phase 2 data showed significant liver fat reduction (approximately 60-70% relative reduction by MRI-PDFF at 24 weeks) with about 10% weight loss. The MASH biopsy data is pending.

CagriSema (Novo Nordisk)

A co-formulation of semaglutide and cagrilintide (a long-acting amylin analog). Amylin works synergistically with GLP-1 to suppress appetite. In the REDEFINE-1 obesity trial, CagriSema produced approximately 22% weight loss at 68 weeks, exceeding semaglutide alone. A dedicated MASH trial hasn’t been announced, but with weight loss of that magnitude, substantial liver benefits are expected.

FGF21 analogs (several companies)

Fibroblast growth factor 21 (FGF21) is a metabolic hormone that regulates glucose and lipid metabolism. Several companies are developing FGF21 analogs and receptor agonists:

• Efruxifermin (Akero Therapeutics): Phase 2b data showed significant liver fat reduction and NASH improvement. The HARMONY phase 3 trial is underway.
• Pegozafermin (89bio): Phase 2 data showed dose-dependent liver fat reduction and fibrosis improvement. Phase 3 (ENLIVEN) is ongoing.

FGF21 analogs work through a different mechanism than GLP-1s or resmetirom, making them potential combination partners.

THR-beta agonists (beyond resmetirom)

Other companies are developing THR-beta agonists, though resmetirom has a significant first-mover advantage. The class effect appears robust, but differentiation on efficacy, safety, or convenience will determine whether competitors find a niche.

What Does the MASLD Name Change Mean for Research?

The June 2023 Delphi consensus that renamed NAFLD to MASLD and NASH to MASH has practical implications for clinical trial design and interpretation.

Classification changes: Under MASLD criteria, patients need at least one cardiometabolic risk factor in addition to hepatic steatosis. This excludes a small minority (about 2-5%) of NAFLD patients who have steatosis without any metabolic risk factors. These patients now fall under “cryptogenic steatotic liver disease.”

Impact on existing data: About 98% of patients who met NAFLD criteria also meet MASLD criteria, per a 2023 analysis by Younossi et al. in Gastroenterology. So existing trial data conducted under NAFLD/NASH nomenclature is still applicable to MASLD/MASH patients.

New trial designs: All new NASH trials use MASH terminology and MASLD diagnostic criteria. The ESSENCE and SYNERGY-MASH trials use the updated nomenclature.

A separate category: MetALD. The new classification system created a category called MetALD (metabolic and alcohol-related liver disease) for patients who have both metabolic risk factors and moderate alcohol consumption (140-350g/week for women, 210-420g/week for men). This group was previously difficult to classify and was often excluded from NAFLD trials. Future trials may specifically target MetALD.

Bottom line: Pipeline drugs like survodutide and FGF21 analogs could expand treatment options by 2028.

Myth vs. Fact: Setting the Record Straight

Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.

Myth: Fatty liver only happens to people who drink alcohol. Fact: Non-alcoholic fatty liver disease (now called MASLD) affects about 25 percent of adults globally and is the most common chronic liver disease in the world. Alcohol isn’t required.

Myth: Fatty liver isn’t a serious condition. Fact: Simple steatosis can progress to NASH, fibrosis, cirrhosis, and liver cancer. NASH is now a leading reason for liver transplantation. Each fibrosis stage increase correlates with 40-50 percent higher all-cause mortality.

Myth: There’s no real treatment for fatty liver. Fact: FDA approved resmetirom (Rezdiffra) in March 2024, the first MASH-specific drug. The semaglutide ESSENCE trial showed both NASH resolution and fibrosis improvement. Weight loss of 7 to 10 percent remains the strongest single intervention.

The Path Forward with TrimRx

Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing fatty liver disease and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.

At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24/7 support you deserve.

Our program includes:

• Doctor consultations: professional guidance without the in-person waiting room
• Lab work coordination: baseline health markers monitored properly
• Ongoing support: 24/7 access to specialists for dosage changes and side effect management
• Reliable medication access: FDA-registered, inspected compounding pharmacies prepare Compounded Semaglutide or Compounded Tirzepatide when branded medications aren’t the right fit

Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.

Bottom line: TrimRx provides a streamlined, medically supervised path to access the latest advancements in fatty liver disease and weight management, all from the comfort of home.

FAQ

Which Trial Is Considered the Strongest Evidence for GLP-1s in NASH?

The ESSENCE trial (semaglutide phase 3) is the strongest because it’s the largest randomized biopsy-endpoint trial for a GLP-1 in MASH, and it met both co-primary endpoints including fibrosis improvement. The Newsome 2021 phase 2 trial was foundational but smaller and didn’t achieve significance on fibrosis. SYNERGY-NASH (tirzepatide) had impressive results but was phase 2 with fewer patients.

Has Any Drug Been Shown to Reduce Liver-related Mortality in NASH?

No. None of the completed NASH trials have been powered or designed to detect differences in liver-related mortality or clinical outcomes (decompensation events, transplant need, HCC). All existing evidence is based on surrogate endpoints: histological improvement (NASH resolution, fibrosis regression) and imaging markers (liver fat reduction). Clinical outcome trials would require thousands of patients followed for many years. They’re being discussed but haven’t been launched.

Are the Pipeline Drugs Better Than What’s Currently Available?

Too early to say definitively. The dual glucagon/GLP-1 agonists (survodutide, pemvidutide) produce more weight loss than semaglutide alone, which could translate to better liver outcomes. FGF21 analogs work through a distinct mechanism and might be valuable as combination therapy. But phase 2 data often doesn’t replicate in phase 3, and until we see larger trials with biopsy endpoints, the current leaders remain semaglutide and resmetirom.

Why Do NASH Trials Take So Long?

Three reasons. First, the endpoints require liver biopsies, which are invasive and can only be done at baseline and end-of-study, creating long study durations (typically 48-72 weeks minimum). Second, fibrosis changes slowly, requiring extended treatment periods to detect improvement. Third, recruitment is difficult because patients must have biopsy-confirmed NASH with specific fibrosis stages, and many eligible patients are reluctant to undergo a second biopsy. Non-invasive biomarker endpoints could speed up trials, and the FDA has shown some willingness to accept MRI-PDFF and non-invasive fibrosis markers as surrogate endpoints, though not yet for full approval.

Can the Name Change From NAFLD to MASLD Affect My Treatment?

No. The name change doesn’t alter treatment recommendations. The same medications, lifestyle interventions, and monitoring protocols apply. The change primarily affects research classification and reduces stigma (eliminating the word “fatty”). If you were diagnosed with NAFLD, you now have MASLD. If you had NASH, you now have MASH. Your treatment plan stays the same.

What’s the Most Promising Combination Therapy Approach?

GLP-1 plus resmetirom is the most discussed combination because the mechanisms are complementary. GLP-1s work primarily through weight loss and metabolic improvement; resmetirom works through hepatic THR-beta activation. Neither interferes with the other pharmacologically. No large trial has tested this combination yet, but off-label use in high-risk patients (F3 fibrosis) is already happening. GLP-1 plus FGF21 analog is another combination being explored in early-stage research.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.